Roche third-quarter sales beat forecasts with boost from new multiple sclerosis medicine

The headquarters of Roche AG in Basel, Switzerland.

Gianluca Colla | Bloomberg | Getty Images

The headquarters of Roche AG in Basel, Switzerland.

Roche‘s third-quarter sales rose 6 percent, beating analyst forecasts as the company was helped by better-than-expected revenue from its new multiple sclerosis medicine Ocrevus,
the Swiss drugmaker said on Thursday.

Roche third-quarter sales were 13.1 billion Swiss francs ($13.37 billion), compared to the 13.04 billion francs average estimate by analysts in a Reuters poll. Sales of Ocrevus were 308 million francs, better than the poll average of 228 million and accelerating from 192 million francs in the second quarter.

Source link

About the Author

Leave A Response